Archiv
Archiv anzeigen:
bis


Managing Hemophagocytic Lymphohistiocytosis

Brady L. Stein, MD, MHS reviewing La Rosée P et al. Blood 2019 Jun 6

Consensus recommendations from an expert panel


Enzalutamide for Hormone-Sensitive Metastatic Prostate Cancer

Robert Dreicer, MD, MS, MACP, FASCO reviewing Davis ID et al. N Engl J Med 2019 Jun 2

Survival was significantly prolonged by combining standard ADT with enzalutamide than with a first-generation androgen-receptor.


Alpelisib for PIK3CA-Mutated Breast Cancer

William J. Gradishar, MD reviewing André F et al. N Engl J Med 2019 May 16

Progression-free survival was significantly longer with fulvestrant plus alpelisib than with fulvestrant plus placebo.


Laparoscopic Distal Gastrectomy for Locally Advanced Gastric Cancer

David H. Ilson, MD, PhD reviewing Yu J et al. JAMA 2019 May 28

Disease-free survival at 3 years was noninferior with laparoscopic versus open distal gastrectomy.


Reversal of Direct Oral Anticoagulants

Brady L. Stein, MD, MHS reviewing Cuker A et al. Am J Hematol 2019 Jun

An Anticoagulation Forum guideline provides recommendations on the use of DOAC reversal agents.


VTE Recurrence After Negative D-Dimer Testing

Brady L. Stein, MD, MHS reviewing Kearon C et al. J Thromb Haemost 2019 Apr 29

The 5-year risk for recurrence was nearly 30% in men with unprovoked venous thromboembolism, despite negative D-dimer testing.


Atezolizumab plus Bevacizumab for Advanced Renal Cell Cancer

Robert Dreicer, MD, MS, MACP, FASCO reviewing Rini BI et al. Lancet 2019 May 9, Pilié PG and Jonasch E. Lancet 2019 May 9

Progression-free survival and safety were better with this combination therapy than with standard sunitinib treatment.


The Impact of Prediagnosis 5-ARIs on Men with Prostate Cancer

Robert Dreicer, MD, MS, MACP, FASCO reviewing Sarkar RR et al. JAMA Intern Med 2019 May 6

Use of 5α-reductase inhibitors was associated with delayed diagnosis and worse mortality.


Platelet Autoantibody Testing for Immune Thrombocytopenia

Brady L. Stein, MD, MHS reviewing Vrbensky JR et al. J Thromb Haemost 2019 May

Specificity was high, but sensitivity was low; thus, autoantibody testing may rule in but not rule out ITP.


Targeting Myeloma with CAR T-Cells

Michael E. Williams, MD, ScM reviewing Raje N et al. N Engl J Med 2019 May 2

Relapsed or refractory patients had high response rates with anticipated, manageable toxicities.


Archiv
Seite von 81
Editorial Member Board Empfehlungen

Prof. Dr. med. Christoph Rochlitz

Chefarzt Onkologie
Universitätsspital Basel

E-Mail: E-Mail anzeigen

Liebe Kolleginnen und Kollegen!

In der vorliegenden Ausgabe von NEJM Journal Watch möchte ich Ihnen gerne wieder einige rezent publizierte Studien aus dem Bereich Onkologie/Hämatologie näherbringen.

Kommentar weiterlesen

Do CDK4/6 Inhibitors Improve Overall Survival in Advanced Breast Cancer?

William J. Gradishar, MD reviewing Turner NC et al. N Engl J Med 2018 Oct 20

Overall survival trended longer with the addition of palbociclib to endocrine therapy in patients with ER-positive/HER2-negative metastatic disease.


Immunotherapy for Breast Cancer Has Arrived

William J. Gradishar, MD reviewing Schmid P et al. N Engl J Med 2018 Oct 20

Adding atezolizumab to nab-paclitaxel prolonged progression-free survival in patients with metastatic triple-negative breast cancer.


Brigatinib for ALK-Positive, Non–Small-Cell Lung Cancer

Anne S. Tsao, MD reviewing Camidge DR et al. N Engl J Med 2018 Sep 25

Progression-free survival was prolonged with front-line brigatinib versus crizotinib.


Front-Line Therapy for Extensive-Stage, Small Cell Lung Cancer: A New Standard

Anne S. Tsao, MD reviewing Horn L et al. N Engl J Med 2018 Sep 25

Adding atezolizumab to chemotherapy significantly improved overall and progression-free survival.


A New Standard of Care for Squamous Non–Small-Cell Lung Cancer

Anne S. Tsao, MD reviewing Paz-Ares L et al. N Engl J Med 2018 Sep 25

Adding the PD-1 inhibitor pembrolizumab to carboplatin-taxane chemotherapy significantly improved response and survival.


Durvalumab After Chemoradiation for Advanced Non–Small-Cell Lung Cancer

Anne S. Tsao, MD reviewing Antonia SJ et al. N Engl J Med 2018 Sep 25

Two-year overall survival was significantly improved with durvalumab versus placebo.


Omission of Axillary Dissection for Minimal Node-Positive Breast Cancer

William J. Gradishar, MD reviewing Galimberti V et al. Lancet Oncol 2018 Sep 5

Long-term follow-up data confirm that axillary dissection is unnecessary in patients with minimal tumor burden in the sentinel nodes.


Olaparib plus Abiraterone for Advanced Prostate Cancer

Robert Dreicer, MD, MS, MACP, FASCO reviewing Clarke N et al. Lancet Oncol 2018 Jul

Progression-free survival was significantly longer with olaparib than with placebo.


Combination Immunotherapy for Metastatic Melanoma with Brain Metastases

Sunandana Chandra, MD, MS reviewing Tawbi HA et al. N Engl J Med 2018 Aug 23, Turajlic S and Larkin J. N Engl J Med 2018 Aug 23

Ipilimumab plus nivolumab proved safe and efficacious in a phase II trial.


First-Line Lenvatinib vs. Sorafenib for Unresectable Hepatocellular Carcinoma

David H. Ilson, MD, PhD reviewing Kudo M et al. Lancet 2018 Feb 9, Reig M and Bruix J. Lancet 2018 Feb 9

Overall survival was noninferior and progression-free survival and response were superior with lenvatinib.